Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 30, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan"). This plan is notionally held in GSK Ordinary Share ADRs. On August 26, 2005, an increase in the notional allocation of Ordinary Share ADRs occurred at a price of $47.44 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rule 3.1.4R(1)(a) regarding the transaction of Mr. R Greig.
Investor Verification Points
- Verify the specific impact of the notional allocation increase on the US Retirement Savings Plan.
- Confirm the identity of Mr. R Greig and his role within the company to assess the significance of the transaction.
- Note that this filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.